Sabaa Pharmaceutical’s losses widen 940.5% in Q1

Updated 6/2/2024 9:28:00 AM
Sabaa Pharmaceutical’s losses widen 940.5% in Q1

Arab Finance: Sabaa International for Pharmaceutical and Chemical Industry (SIPC) incurred net losses after tax of EGP 1.019 million during the first quarter (Q1) of 2024, up by 940.49% from EGP 98,021 in the year-ago quarter, according to the company’s financial statement.

Revenues dropped to EGP 1.665 million during the January-March period of this year, from EGP 2.563 million during the first three months of 2023.

Sabaa is an Egypt-based company engaged in the pharmaceutical sector. The company’s generic product portfolio includes products focused on different therapeutic categories.

Related News